More than 100 years after its discovery, Bayer Corp. is celebrating the success of aspirin.
More than 100 years after its discovery, Bayer Corp. is celebrating the success of aspirin.
In August, the Pittsburgh-based company initiated a comprehensive marketing campaign to draw attention to the multiple uses of its "wonder drug." Basically, the company is attempting to give a marketing face-lift to one of the oldest common medicines.
Aspirin was born in August 1897 when a young German chemist discovered a stable form of acetylsalicylic acid, aspirin's active ingredient. Two years later, Bayer® Aspirin hit the market and quickly became the world's most commonly used pain reliever. By 1915, it was available without a prescription.
How the product actually worked in the body, however, was not understood until 1971. That year, British pharmacologist John Vane discovered that the anti-inflammatory properties of salicylates are a result of their ability to inhibit the body's production of chemical mediators, or prostaglandins, which promote inflammation and pain. Vane received the Nobel Prize for Medicine in 1982 for his medical breakthrough.
Today, approximately 29 billion aspirin tablets are consumed in America each year. Bayer manufactures 11 billion of those tablets.
Studies linking daily doses of aspirin with prevention of heart attacks and strokes have boosted product sales in recent years. The FDA may also approve aspirin for treatment during a suspected heart attack; for the prevention of stroke in women after a minor stroke; after a minor stroke in men and women; for prevention of a first heart attack in certain high-risk groups; and in dosages lower than previously recommended for treatment of minor stroke and heart attack.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.